Assertio Announces Leadership Transition
Assertio (Nasdaq: ASRT) appointed director Mark L. Reisenauer as CEO effective immediately; current CEO Brendan P. O’Grady will depart.
The company said it will release third-quarter 2025 results on November 10, 2025 after market close and host a live webcast at 4:30 p.m. ET the same day. Management expects to update guidance within the current range on that call. Reisenauer joined the Board in January 2025 and has over 30 years of commercial experience, including growing U.S. commercial sales to nearly $5 billion at Astellas.
Assertio (Nasdaq: ASRT) ha nominato l'amministratore Mark L. Reisenauer come CEO con effetto immediato; l'attuale CEO Brendan P. O’Grady partirà. L'azienda ha comunicato che diffonderà i risultati del terzo trimestre 2025 il 10 novembre 2025 dopo la chiusura del mercato e terrà una webcast in diretta alle 16:30 ET lo stesso giorno. La direzione si aspetta di aggiornare le previsioni entro l'intervallo vigente in quella chiamata. Reisenauer è entrato nel Consiglio a gennaio 2025 e ha oltre 30 anni di esperienza commerciale, incluso lo sviluppo delle vendite commerciali statunitensi a quasi $5 miliardi presso Astellas.
Assertio (Nasdaq: ASRT) nombró al director Mark L. Reisenauer como CEO con efecto inmediato; el actual CEO Brendan P. O’Grady se irá.
La compañía dijo que publicará los resultados del tercer trimestre de 2025 el 10 de noviembre de 2025 después del cierre del mercado y realizará una webcast en vivo a las 4:30 p.m. ET ese mismo día. La dirección espera actualizar las perspectivas dentro del rango actual durante esa llamada. Reisenauer se unió a la Junta en enero de 2025 y tiene más de 30 años de experiencia comercial, incluyendo el crecimiento de las ventas comerciales en EE. UU. a casi $5 mil millones en Astellas.
Assertio (Nasdaq: ASRT) 이사 Mark L. Reisenauer를 CEO로 임명하며 즉시 발효; 현 CEO Brendan P. O’Grady는 퇴임합니다.
회사는 2025년 11월 10일 장 마감 후 2025년 3분기 실적을 발표하고 같은 날 동시에 오후 4시 30분(E.T.)에 생 webcast를 주최한다고 밝혔습니다. 경영진은 그 통화에서 현재 범위 내로 가이던스를 업데이트할 것으로 기대합니다. Reisenauer은 2025년 1월 이사회에 합류했고 Astellas에서 미국 내 상업 매출을 거의 $50억까지 성장시키는 등 30년이 넘는 상업적 경험을 보유하고 있습니다.
Assertio (Nasdaq: ASRT) a nommé au poste de PDG le directeur Mark L. Reisenauer avec effet immédiat; l'actuel PDG Brendan P. O’Grady quittera l'entreprise.
La société a déclaré qu'elle publiera les résultats du troisième trimestre 2025 le 10 novembre 2025 après la clôture du marché et organisera une webdiffusion en direct à 16 h 30 HE le même jour. La direction prévoit mettre à jour les prévisions dans la plage actuelle lors de cet appel. Reisenauer a rejoint le conseil en janvier 2025 et possède plus de 30 ans d'expérience commerciale, notamment en faisant passer les ventes commerciales américaines à près de 5 milliards de dollars chez Astellas.
Assertio (Nasdaq: ASRT) ernannte den Direktor Mark L. Reisenauer mit sofortiger Wirkung zum CEO; der derzeitige CEO Brendan P. O’Grady wird das Unternehmen verlassen.
Das Unternehmen gab bekannt, dass es die Ergebnisse für das dritte Quartal 2025 am 10. November 2025 nach Börsenschluss veröffentlicht und am selben Tag um 16:30 Uhr ET einen Live-Webcast durchführen wird. Das Management erwartet, dass es in diesem Call die Guidance im aktuellen Rahmen anpasst. Reisenauer trat im Januar 2025 dem Vorstand bei und verfügt über mehr als 30 Jahre kommerzielle Erfahrung, darunter die Steigerung des US-amerikanischen kommerziellen Umsatzes auf fast 5 Milliarden Dollar bei Astellas.
Assertio (Nasdaq: ASRT) عينت المدير Mark L. Reisenauer رئيساً تنفيذياً اعتبارًا من الآن؛ سيفارق المدير التنفيذي الحالي Brendan P. O’Grady المنصب.
قالت الشركة إنها ستصدر نتائج الربع الثالث من 2025 في 10 نوفمبر 2025 بعد إغلاق السوق وتستضيف بثًا مباشرًا على الويب في 4:30 مساءً بتوقيت شرق الولايات المتحدة في اليوم نفسه. تتوقع الإدارة تحديث التوجيه ضمن النطاق الحالي خلال تلك المكالمة. انضم Reisenauer إلى المجلس في يناير 2025 ولديه أكثر من 30 عامًا من الخبرة التجارية، بما في ذلك زيادة المبيعات التجارية الأمريكية إلى نحو 5 مليار دولار لدى Astellas.
Assertio (纳斯达克：ASRT) 任命董事 Mark L. Reisenauer 为首席执行官，立即生效；现任首席执行官 Brendan P. O’Grady 将离任。
公司表示将于 2025 年 11 月 10 日盘后公布 2025 年第三季度业绩，并在同一天举行现场网络直播，时间为 美东时间下午 4:30。 管理层预计在那次电话会议上 在当前区间内更新指引。 Reisenauer 于 2025 年 1 月加入董事会，拥有超过 30 年的商业经验，包括在 Astellas 将美国商业销售增长到接近 50 亿美元。
- Immediate CEO appointment of an industry veteran with commercial track record
- Board continuity: Reisenauer has served on the Board since January 2025
- Near-term catalyst: Q3 2025 results and guidance update scheduled for Nov 10, 2025
- CEO departure of Brendan P. O’Grady may cause near-term leadership transition risk
- No guidance tightening: company expects to update guidance only within the current range
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately
Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time
LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that its Board of Directors (the “Board”) has appointed director Mark L. Reisenauer as the Company’s Chief Executive Officer (“CEO”), effective immediately. As part of this transition, current CEO Brendan P. O’Grady will be departing the Company.
Heather L. Mason, Chair of the Board of Directors, stated, “After significant deliberation, the Board determined that Mark is best suited to lead Assertio through its next phase. As we enter 2026, our goal is to accelerate growth while enhancing efficiency to deliver long-term value for shareholders and patients. Given Mark’s extensive experience successfully building and launching franchises and products in both the oncology and specialty spaces and his in-depth knowledge of our business, he is highly qualified to take on this role. In Mark’s new role, Assertio stakeholders will be able to further benefit from his track record of leading commercially driven organizations, creating strategies, driving lifecycle management and assessing business development opportunities.”
Reisenauer said, “I believe Assertio has significant potential and I look forward to working closely with our Board, leadership team and employees to reach more patients with our medicines and create value for shareholders. The team and I will be providing further updates on our third-quarter earnings call.”
Mason continued, “The Board would like to thank Brendan for his contributions to Assertio and we wish him further success in the future.”
O’Grady said, “It has been a privilege to lead at Assertio. I am deeply grateful to our employees for their dedication and hard work, which has driven meaningful progress in a short time.”
Third Quarter 2025 Conference Call and Financial Results
Assertio today also announced that it will release third quarter 2025 financial results on November 10, 2025, after the market close. Additionally, Assertio’s management will host a live webcast conference call at 4:30 p.m. Eastern Time on November 10 to discuss the financial results and provide business updates on the Company’s 2025 strategic plans. The Company expects to update guidance within the current range at that time.
To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.
A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website.
Mark Reisenauer Biography
Mr. Reisenauer, who joined Assertio’s Board in January 2025, has more than 30 years of experience successfully commercializing and launching products in the oncology space. He previously served as President of U.S. Commercial at Astellas Pharmaceuticals Inc., where he grew sales to nearly
About Assertio
Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products in oncology, neurology, and pain management. To learn more about Assertio, visit www.assertiotx.com.
Forward Looking Statements
Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio, including risks related to the subject matter of this communication and our ability to realize the benefits from our operating model, deliver or execute on our business strategy, including to expand or diversify our asset base and market reach and drive cash flows and growth, successfully integrate new assets, and explore new business development initiatives. All statements other than historical facts may be forward-looking statements and can be identified by words such as “anticipate,” “believe,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may,” “objective,” “opportunity,” “outlook,” “plan,” “position,” “potential,” “predict,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “would,” “will,” “aim” or other similar expressions that convey the uncertainty of future events or outcomes and are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio, including the risks described in Assertio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) and in other filings Assertio makes with the SEC from time to time.
Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law.
Contact
Ajay Patel
Chief Financial Officer
apatel@assertiotx.com
FAQ
Who is the new CEO of Assertio (ASRT) and when is the appointment effective?
When will Assertio (ASRT) report third-quarter 2025 results and hold the earnings call?
Will Assertio (ASRT) update guidance on the November 10, 2025 call?
What is Mark Reisenauer’s industry experience relevant to Assertio (ASRT)?
Where can investors access Assertio’s (ASRT) Nov 10, 2025 webcast and replay?
